Ratings MorphoSys AG OTC Markets

Equities

MPSYF

DE0006632003

Delayed OTC Markets Other stock markets 09:30:02 2024-06-21 am EDT			5-day change	1st Jan Change
72.38 ^USD	+1.40%		0.00%	+76.54%

Jun. 10	MorphoSys AG(XTRA:MOR) dropped from S&P Global BMI Index	CI
Jun. 06	MorphoSys AG Announces Board Changes	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MORPHOSYS AG	+76.54%	2.73B	-
MODERNA, INC.	+34.51%	51.51B	B-
IQVIA HOLDINGS INC.	-6.67%	39.03B	B
LONZA GROUP AG	+34.92%	38.91B	A
CELLTRION, INC.	-12.11%	26.68B	C
ICON PUBLIC LIMITED COMPANY	+12.95%	26.13B	B-
ALNYLAM PHARMACEUTICALS, INC.	-14.38%	19.91B	B
UNITED THERAPEUTICS CORPORATION	+43.37%	13.71B	B+
MEDPACE HOLDINGS, INC.	+30.83%	12.38B	C+
BIO-TECHNE CORPORATION	-4.55%	11.74B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes